In India COPD is estimated to affect more than 100 million people which accounts for more than 9.5 percent of all deaths. So an effective solution to its management is sought. Keeping this in mind, a market leader in pharmaceuticals, GlaxoSmithKline has recently launched one of the first once daily single-inhaler triple therapy (SITT) named “Trelegy Ellipta” (fluticasone furoate/umeclidinium/vilanterol) for Chronic Obstructive Pulmonary Disease (COPD) patients in India. Trelegy is administered through the innovative Ellipta inhaler which provides accurate dosage via its consistent dose delivery mechanism and is associated with less inhaler teaching time than other commonly used inhalers.
The product launch follows the approval by the Drugs Controller General of India (DGCI) of Trelegy Ellipta as a maintenance treatment to prevent and relieve symptoms associated with COPD in patients aged 18 and above.